Hutsell Blake A, Cheng Kejun, Rice Kenner C, Negus Sidney Stevens, Banks Matthew L
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Chemical Biology Branch, National Institute on Alcohol Abuse and Alcoholism, National Institute of Health, Bethesda, MD, USA.
Addict Biol. 2016 Mar;21(2):360-73. doi: 10.1111/adb.12206. Epub 2015 Jan 8.
The dynorphin/kappa opioid receptor (KOR) system has been implicated as one potential neurobiological modulator of the abuse-related effects of cocaine and as a potential target for medications development. This study determined effects of the KOR antagonist nor-binaltorphimine (nor-BNI) on cocaine self-administration under a novel procedure that featured two daily components: (1) a 2-hour 'choice' component (9:00-11:00 am) when monkeys could choose between food pellets and cocaine injections (0-0.1 mg/kg per injection, intravenous) and (2) a 20-hour 'extended-access' component (noon to 8:00 am) when cocaine (0.1 mg/kg per injection) was available under a fixed-ratio schedule to promote high daily cocaine intakes. Rhesus monkeys (n = 4) were given 14 days of exposure to the choice + extended-access procedure then treated with nor-BNI (3.2 or 10.0 mg/kg, intramuscular), and cocaine choice and extended-access cocaine intake were evaluated for an additional 14 days. Consistent with previous studies, cocaine maintained both a dose-dependent increase in cocaine choice during choice components and a high level of cocaine intake during extended-access components. Neither 3.2 nor 10 mg/kg nor-BNI significantly altered cocaine choice or extended-access cocaine intake. In two additional monkeys, nor-BNI also had no effect on cocaine choice or extended-access cocaine intake when it was administered at the beginning of exposure to the extended-access components. Overall, these results do not support a major role for the dynorphin/KOR system in modulating cocaine self-administration under these conditions in non-human primates nor do they support the clinical utility of KOR antagonists as a pharmacotherapeutic strategy for cocaine addiction.
强啡肽/κ阿片受体(KOR)系统被认为是可卡因滥用相关效应的一种潜在神经生物学调节因子,也是药物开发的一个潜在靶点。本研究采用一种新的程序,该程序包括两个每日环节,以此来确定KOR拮抗剂去甲二氢吗啡酮(nor-BNI)对可卡因自我给药的影响:(1)一个2小时的“选择”环节(上午9:00至11:00),在此期间猴子可以在食物颗粒和可卡因注射(每次注射0 - 0.1毫克/千克,静脉注射)之间进行选择;(2)一个20小时的“延长获取”环节(中午至上午8:00),在此期间可卡因(每次注射0.1毫克/千克)按照固定比例给药,以促进每日高可卡因摄入量。恒河猴(n = 4)接受14天的选择 + 延长获取程序暴露,然后用nor-BNI(3.2或10.0毫克/千克,肌肉注射)进行治疗,并在另外14天内评估可卡因选择和延长获取可卡因摄入量。与先前的研究一致,可卡因在选择环节中维持了可卡因选择的剂量依赖性增加,并且在延长获取环节中维持了高水平的可卡因摄入量。3.2毫克/千克和10毫克/千克的nor-BNI均未显著改变可卡因选择或延长获取可卡因摄入量。在另外两只猴子中,当在延长获取环节开始时给予nor-BNI时,它对可卡因选择或延长获取可卡因摄入量也没有影响。总体而言,这些结果不支持强啡肽/KOR系统在这些条件下调节非人类灵长类动物可卡因自我给药中起主要作用,也不支持KOR拮抗剂作为可卡因成瘾药物治疗策略的临床实用性。